Skip to content
1st July 2022

Effects of Multiple Dose Treatment with an Anti-KIT Antibody, CDX-0159, in Chronic Spontaneous Urticaria

4th February 2022

Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study

1st February 2022

The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria

1st September 2021

CDX-0159, an anti-KIT Antibody, Demonstrates Rapid and Sustained Clinical Response and Improved Quality of Life in Patients with Chronic Inducible Urticaria

1st July 2021

The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria

1st April 2021

Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies

1st June 2020

CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study

1st November 2019

CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases

Top